Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 30Rectal Neoplasms 21Esophageal Neoplasms 15Colorectal Neoplasms 15Pancreatic Neoplasms 12Lung Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Prostatic Neoplasms 10Adenocarcinoma Of Esophagus 9Stomach Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Head and Neck Neoplasms 8Sarcoma 7Esophageal Squamous Cell Carcinoma 7Neoplasms 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Intraductal, Noninfiltrating 5Urinary Bladder Neoplasms 4Inflammatory Breast Neoplasms 4Fallopian Tube Neoplasms 4Breast Neoplasms, Male 4Breast Carcinoma In Situ 4Brain Neoplasms 4Recurrence 3Neoplasm Metastasis 3Kidney Neoplasms 3Glioma 3Glioblastoma 3

Interventions

Mitomycin 11Gemcitabine 7BCG Vaccine 4Imiquimod 2Administration, Intravesical 2viscum album peptide 1pemigatinib 1pembrolizumab 1erdafitinib 1dodecyl maltoside 1Water 1VPM1002 recombinant BCG vaccine 1VB4-845 1Therapeutics 1Photochemotherapy 1Neoadjuvant Therapy 1Interferon-alpha 1Hyaluronic Acid 1High-Intensity Interval Training 1Gels 1Ethacrynic Acid 1Epirubicin 1Educational Status 1Doxorubicin 1Docetaxel 1Dihematoporphyrin Ether 1Cystoscopy 1Celecoxib 1BCG Connaught 15-aminolevulinic acid hexyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Non-Muscle Invasive Bladder Neoplasms × Neoadjuvant Therapy × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔